AMEXIndustrialsAerospace & DefenseSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SIF yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Gross profit growth to sustain or exceed $5.66 million quarterly | Profit improves with net income rising to $2.65 million and gross profit to $5.66 million. | Intact | gross profit falls below $5.66 million quarterly average | Gross profit: $3.422M FY2026-Q3; GAAP. Published target: >= $5.66 million per quarter. Target period is not explicitly aligned with this observation. Aug 10, 20263,422,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 28, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
SIF is a higher-risk, small-cap industrial business with a growth-and-profitability improvement thesis. The thesis is on watch: sales and gross profit have improved, but earnings quality is still classified as loss-making and recent performance is neutral.
The valuation is described as cheap, while the model shows a 1.09 premium versus peers and an expectations gap of -0.14, so the signals are mixed. Pricing is tagged as justified, with low fragility; the evidence does not show that expectations are unusually stretched.
Near term, management’s focus on revenue growth and gross profit has matched recent progress, while net income from continuing operations improved over the first six and nine months of 2026. However, results have been erratic, the risk level is elevated, and a guidance cut on the next call is a stated concern. Over the multi-year view, continued progress depends on sustaining growth and turning operating gains into more consistent earnings.
The next call matters: a guidance cut could signal weaker execution, while continued backlog conversion and customer demand would support the growth thesis. Sector conditions are another swing factor, with industrial bellwethers’ results and guidance indicating whether the current sector headwind eases or worsens.
For the next one to three years, SIF’s case depends on converting sales growth and better gross profit into steady profitability, against elevated execution and sector risks. The signal is mixed and the thesis remains on watch. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit improves with net income rising to $2.65 million and gross profit to $5.66 million. |
| Intact |
| net income falls below $2.65 million quarterly average |
Net income: $-40,000 FY2026-Q3; GAAP. Published target: >= $2.65 million per quarter. Target period is not explicitly aligned with this observation. Aug 10, 2026-40,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of at least 7.6% annually | A primary condition in SIFCO Industries Inc's published investment case. The stated target is >=7.6% YoY. | Intact | YoY revenue growth falls below 7.6% next year | Revenue growth: 18.33% FY2026-Q3; GAAP. Published target: >=7.6% YoY. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 10, 202618.329939 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Third Quarter Results • Net sales in the third quarter of fiscal 2026 increased 18.3% to $26.1 million, compared with $22.1 million for the same period in fiscal 2025.” “Customer demand remains strong, and our backlog provides continued visibility to future activity.” Revenue was $26.444 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.